Analysis of risk factors of mortality in rheumatoid arthritis patients with interstitial lung disease: a nationwide, population-based cohort study in Taiwan

Kooi-Heng Ng, Der-Yuan Chen, Ching-Heng Lin, Wen-Cheng Chao, Hsin-Hua Chen

ABSTRACT
Objective To examine the risk and risk factors of mortality in patients with rheumatoid arthritis (RA) with interstitial lung disease (ILD).
Methods Using the 1997–2013 Taiwanese National Health Insurance Research Database, we identified 3289 incident patients with RA by using International Classification of Diseases, Ninth Revision codes from 2001 to 2013, and 214 patients developed ILD subsequently. We matched (1:10) RA-ILD with controls for sex, age, time of ILD diagnosis and disease duration. In addition, we conducted propensity score matching (PSM) (1:1) for selected comorbidities to choose RA-ILD patients and controls. Using the Cox proportional hazard model, we estimated the association of mortality with ILD for the two matched populations and assessed factors associated with mortality among 214 RA-ILD patients, shown as adjusted HRs (aHRs) with 95% CIs.

Results In the populations selected before and after PSM, we included 164 and 155 patients with RA-ILD and 1640 and 155 controls, respectively. ILD was associated with mortality in the population before PSM (aHR, 1.73; 95% CI 1.19 to 2.52) and in the PSM population (HR 4.38; 95% CI 2.03 to 9.43). Among 214 patients with RA-ILD, age (aHR 1.04; 95% CI 1.03 to 1.08), chronic obstructive pulmonary disease (COPD) (aHR 2.12; 95% CI 1.25 to 3.58), diabetes mellitus (DM) with end-organ damage and corticosteroid dose (prednisolone equivalent, mg/day) (aHR 1.09; 95% CI 1.07 to 1.11) were associated with mortality in RA-ILD.

Conclusion This population-based cohort study showed that ILD was associated with risk of mortality in patients with RA, and risk factors associated with mortality in patients with RA-ILD included age, COPD, DM with end-organ damage and average daily prednisolone dose.

INTRODUCTION
Rheumatoid Arthritis (RA) is a systemic autoimmune disease affecting about 0.46% of the worldwide population. The most common extra-articular manifestation of RA is lung involvement, which comprises up to 60% of the RA population. Basically, any part of the lungs can be affected, that is, pleura, parenchyma, airways and pulmonary vasculatures. Lung parenchyma is the most commonly affected compartment causing interstitial lung disease (ILD). The incidence and prevalence of RA-ILD varied widely due to variable case definitions and sample sizes. A systemic review showed the prevalence of RA-ILD...
ranged from 1.8% to 67% (median: 24.9%).4 The incidence of RA-ILD in Taiwan’s nationwide population-based cohort study was 0.7%, with an incidence rate ratio (IRR) of 9.05.5 A recent meta-analysis by Qiu et al6 has shown 10 factors associated with increased risk of mortality in RA-ILD: older age, male sex, smoking history, lower diffusing capacity of the lung for carbon monoxide, lower forced vital capacity predicted, higher composite physiological index, usual interstitial pneumonia (UIP) pattern on high-resolution CT, emphysema presence and acute exacerbation of ILD. However, the majority of the studies were single-centre studies. There were very limited studies on the influence of treatment, especially biological therapy, on mortality in RA-ILD.7,8

We conducted a nationwide, population-based cohort study to compare the incidence of death between RA patients with ILD and RA patients without ILD. We also examine the predictors of RA-ILD mortality, concentrating on patient-specific variables and treatment-specific variables, by using the Taiwanese National Health Insurance Research Database (NHIRD).

METHODS
Study design
This was a nationwide, population-based, matched cohort study.

Data source
Claims data from 1997 to 2013 were retrieved from the Taiwanese NHIRD. Since 1995, the National Health Insurance (NHI) was initiated in Taiwan. It is a compulsory insurance programme covering 99% of the Taiwanese population. The National Health Research Institute manages the NHIRD and releases claims data for research purposes and The Bureau of NHI routinely audits and monitors claims data to avoid the inclusion of fraudulent data.

The NHIRD contains registration files and comprehensive claims data for all ambulatory and inpatient services, including information regarding demographics, residence, prescription medications, diagnoses, medical expenditure, surgeries, procedures and examinations. All patients with major illnesses are registered in the catastrophic illness registry if the categorisation is agreed on regardless of disease severity after a thorough review of original charts by two independent specialists. There after, a catastrophic illness certificate will be issued to these patients whom the medical services expenses will be exempted.

Patients identifications from the entire Taiwan population
Patients with RA who were registered in the catastrophic illness registry (International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 714.0, 714.30–714.33) were retrieved. All patients newly diagnosed with RA from 2001 to 2013 were included. Exclusion criteria were a diagnosis of ILD (ICD-9-CM codes 515, 516.3, 516.8, 516.9, 517) before the time of RA diagnosis or overlapping diagnosis of systemic autoimmune rheumatic diseases, including systemic lupus erythematosus (ICD-9-CM code 710.0), Sjogren’s syndrome (ICD-9-CM code 710.2), dermatomyositis (ICD-9-CM code 710.3), polymyositis (ICD-9-CM code 710.4) and systemic sclerosis (ICD-9-CM code 710.1). The index date for patients with RA was defined as the RA catastrophic illness certificate application date.

Definition of ILD
Patients with RA identified above will be further divided into ILD and non-ILD groups. In order to improve the validity of ILD diagnosis, we defined ILD as follows: (1) at least one outpatient or inpatient visit using ICD-9-CM code 515, 516.3, 516.8, 516.9 or 517 and (2) a radiological or pathological diagnosis using the appropriate NHI code (online supplemental table A) within 6 months before or after the first date of diagnosis. If the radiographic or pathological ILD diagnosis was made after the first outpatient or inpatient visit, we required at least another outpatient or inpatient visit with ILD diagnosis. Exclusion criteria were those without insured amount and those without urbanisation categorisation. The index date was the first date of ambulatory or inpatient visit with an ILD diagnosis.

Age, sex, year of ILD diagnosis and disease duration-matched RA population
We matched (1:10) RA-ILD patients with RA patients without a diagnosis of ILD during the follow-up period for age, sex, year of ILD diagnosis date and disease duration.

Propensity score-matched RA population
In addition, using the 1:10 matched RA population mentioned above, we conducted propensity score matching (PSM) for the comorbidities used to calculate the Charlson Comorbidity Index at a ratio of 1:1 to select another RA population to examine the influence of ILD on mortality in patients with RA.

Outcome
The primary outcome was mortality for both groups of patients during the study periods. Data were censored on 31 December 2013 or on the withdrawal date from the NHI for any reason, whichever came first.

Potential confounders
Potential confounders for this study included age, sex, disease duration, urbanisation level of residence, income, comorbidities and medications for RA treatment. The urbanisation level of a residence was categorised according to population density (people/km²); the proportion of agricultural workers, participants with an educational level above college and elderly (aged >65 years); and the number of physicians/10^5 individuals.9 The payroll-related insured amount was used as a proxy of income and was transformed into a categorical variable with two levels. The comorbidities used to calculate
the Charlson Comorbidity Index were considered potential confounders. The presence of comorbidity was defined as having at least one hospitalisation or at least three ambulatory visits with a corresponding ICD-9-CM code within 1 year before the index date. The ICD-9-CM codes of comorbidities are shown in online supplemental table A. RA-related medications included corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), cyclophosphamide, other immunosuppressants (ciclosporin, azathioprine, mycophenolate and mycophenolic acid), conventional synthetic disease-modifying anti-inflammatory drugs (DMARDs) (methotrexate, sulfasalazine, leflunomide and hydroxychloroquine) and biological DMARDs (tumour necrosis factor inhibitor (TNFi), tocilizumab, abatacept and rituximab). Use of RA-related medications at baseline was identified within 1 year before the index date and was adjusted as categorical variables, which may serve as a proxy of baseline RA disease activity. We also adjusted time-averaged dose of RA-related medications during the follow-up period (ie, NSAID, cumulative defined daily dose (cDDD)/day; corticosteroid, prednisolone equivalent dose, mg/day; methotrexate, per 2.5 mg/week, sulfasalazine, cumulative dose/500 mg/day; leflunomide, cDDD/day; cyclophosphamide, cumulative dose/500 mg/month, other immunosuppressants, cDDD/day; TNFi, cDDD/day; tocilizumab, cDDD/day; abatacept, cDDD/day; rituximab, cumulative dose/500 mg/6 months).

Statistical analysis
Continuous variables are presented as mean±SD while categorical data are presented as the percentage of subjects. The χ² test was utilised to evaluate differences between categorical variables whereas the Student’s t-test was used for continuous variables. The mortality of RA-ILD or RA-non ILD was taken as the number of subjects’ death events in percentage. The IRRs and their corresponding 95% CIs were evaluated. Finally, the association of mortality with ILD was assessed using the multivariable Cox regression analysis shown as adjusted HR (aHR) with 95% CIs adjusting for potential confounders. In the PSM population, we conducted a conditional Cox regression analysis to estimate the influence of ILD on the risk of mortality. To examine the impact of covariates on mortality among 214 patients with RA-ILD, we conducted a multivariable Cox regression analysis adjusting for the covariate with a p<0.05 in the univariable Cox regression analysis.

RESULTS
Baseline characteristics
In total, we identified 214 patients with RA-ILD and 30 882 RA-non ILD patients after excluding the criteria mentioned above. Figure 1 shows the flow chart of subject identification. After matching the age of RA, age of ILD diagnosis, gender and disease duration, we were able to identify 164 and 155 patients with RA-ILD patients in the age, sex, year of ILD diagnosis date and disease duration-matched population and the PSM population, respectively. The mean±SD disease duration from RA diagnosis to ILD detection was 3.5±2.8 years. The demographic and clinical characteristics of the study subjects, including the level of urbanisation, patient income, comorbidities and medications, are shown in table 1.

Incidence of mortality in RA patients with ILD and RA patients without ILD
As seen in table 1, the mortality rate was significantly higher in the RA-ILD group compared with the non-ILD group, with the IRR of 2.66 in the pre-PSM population and 2.55 in the PSM population. Among the population before PSM, we found that ILD was significantly associated with the risk of mortality in patients with RA in the univariable model (crude HR 2.69; 95% CI 1.97 to 3.68) and in the multivariable model (aHR 1.73; 95% CI 1.19 to 2.52) using the Cox regression analyses. In the PSM population, ILD was significantly associated with the risk of mortality in patients with RA using the conditional Cox regression model.

Factors associated with mortality in patients with RA-ILD
Online supplemental table 2 indicates the demographics and clinical characteristics of RA-ILD patients, whereas online supplemental table 3 summarises the Cox proportional regression analysis of factors associated with mortality. For patient demographic factors, predictors of mortality included age at ILD diagnosis. With regard to comorbidities, dementia and diabetes mellitus (DM) with end-organ damage were significantly associated with higher mortality across all models. Regarding RA-related medications, only a time-averaged dose of corticosteroid during the follow-up period was significantly associated with mortality in patients with RA-ILD.

DISCUSSION
This nationwide, population-based study showed that ILD significantly increased the risk of mortality in patients with RA, with aHR of 1.75 in the age, sex, disease

Figure 1 Study subject identification flow chart. ILD, interstitial lung disease; RA, rheumatoid arthritis.

Ng K-H, et al. RMD Open 2022;8:e002343. doi:10.1136/rmdopen-2022-002343
There is a strong linkage between RA and COPD and it represents a confounder for the mortality rate in RA.

Exacerbation of ILD and recurrent lungs infection also increases the risk of mortality in RA.

Our study found a significant association between mortality and older age, which is consistent with meta-analysis data. Other patient-specific variables which significantly increase RA-ILD mortality are comorbidities of chronic obstructive pulmonary disease (COPD) and DM with end-organ damage. There is growing evidence that the autoimmune pathway is playing a significant role in emphysema, especially in the RA population.

Smoking is a known risk factor for COPD and it represents a confounder for the association between COPD and RA-ILD mortality. The prevalence of DM is increased in patients with RA, and there is a strong linkage between RA insulin resistance and systemic inflammation induced by proinflammatory cytokines. There is an association between DM and ILD/IPF with an unknown mechanism. Our study has shown that DM with end-organ damage increased RA-ILD mortality. Further study is needed to explore the pathophysiology linkage between DM and RA-ILD.

There are only very limited studies on RA treatment as predictor for RA-ILD mortality. There were also a controversy with regards to the effect of conventional DMARDs and biological DMARDs on RA-ILD onset, progression and mortality. Our report showed average daily prednisolone dose increased RA-ILD mortality. One of the reasons of this association might be due to risk of infections with increase prednisolone usage. Indirectly, it also reflected on increased RA or ILD activity which directly affecting the mortality in RA-ILD group.

There are few limitations in this study. First, lack of smoking data which represents an unmeasured confounder for RA-ILD mortality. However, we have assessed the association of RA-ILD mortality with smoking-related comorbidities, which may partially reflect the impact of smoking. Second, the diagnosis of RA and ILD may be questionable from claim data. W
DM and RA-ILD as well as the effect of RA treatments on RA-ILD progression and mortality.

Author affiliations
1Division of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan
2Department of Rheumatology and Immunology, China Medical University Hospital, Taichung, Taiwan
3College of Medicine, China Medical University, Taichung, Taiwan
4Department of Medical Research, Taichung VGH, Taichung, Taiwan
5School of Medicine, Chung Hsing University, Taichung, Taiwan
6Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung, Taiwan
7Department of Healthcare Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan
8Department of Public Health, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
9Big Data Center, Chung Hsing University, Taichung, Taiwan
10Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
11Department of Computer Science, Tunghai University, Taichung, Taiwan
12Department of Automatic Control Engineering, Feng Chia University, Taichung, Taiwan
13Division of General Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
14Institute of Biomedical Science and Rong Hsing Research Centre for Translational Medicine, Chung Hsing University, Taichung, Taiwan
15School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Acknowledgements The study is based on data from the NHIRD provided by the National Health Insurance Administration and the Ministry of Health and Welfare and managed by the National Health Research Institutes. The interpretation and conclusions do not represent those of the National Health Insurance Administration, the Ministry of Health and Welfare or the National Health Research Institutes. The authors would like to thank the Biostatistics Task Force of Taichung Veterans General Hospital, Taichung, Taiwan, ROC for statistical support. This study has been presented as an abstract at the EULAR 2022 Congress. Chen HH, Chen C, W, and H contributed to the study design, data collection, statistical analysis, and wrote the manuscript. H-H, Chen D, and R performed bioinformatics analysis and wrote the manuscript. H-J designed the study, conducted data analysis and wrote the manuscript. H-C is responsible for the overall content as the guarantor. All authors read and approved the final manuscript.

Contributors C-HL analysed the data and generated figures. K-HN analysed the data and wrote the manuscript. D-YC, C-CHL and W-CP performed bioinformatics analysis and wrote the manuscript. H-CH designed the study, conducted data analysis and wrote the manuscript. H-CHC is responsible for the overall content as the guarantor. The guarantor accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. All authors read and approved the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study was approved by the Institutional Review Board (IRB) of Taichung Veterans General Hospital (IRB number: CE17100B). The requirement for informed consent was waived because detailed personal information was completely anonymised before data analysis.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Wen-Cheng Chao http://orcid.org/0000-0001-9631-8934
Hsin-Hua Chen http://orcid.org/0000-0002-7304-4587

REFERENCES
1 Almutairi K, Nossent J, Preen D, et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. *Rheumatol Int* 2021;41:863–77.
2 Wilsher M, Voight B, Mive D, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. *Respir Med* 2012;106:1441–6.
3 Norton S, Koduri G, Nikiphoro E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. *Rheumatology* 2013;52:99–110.
4 Fazeli MS, Khaychuk V, Wittstock K, et al. Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognostic factors, and treatment landscape. *Clin Exp Rheumatol* 2021;39:1108–18.
5 Ng K-H, Chen D-Y, Lin C-H, et al. Risk of interstitial lung disease in patients with newly diagnosed systemic autoimmune rheumatic disease: a nationwide, population-based cohort study. *Semin Arthritis Rheum* 2020;50:840–5.
6 Qu M, Jiang J, Nian X, et al. Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. *Respir Res* 2021;22:264.
7 Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology biologics register. *Ann Rheum Dis* 2010;69:1086–91.
8 Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. *Autoimmun Rev* 2021:20:102830.
9 Ancelin M-L, Carrierie I, Helmer C, et al. Steroid and nonsteroidal anti-inflammatory drugs, cognitive decline, and dementia. *Neurobiol Aging* 2012;33:2082–90.
10 Deyo RA, Cherkin DC, Siol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992;45:613–9.
11 de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? *Clin Respir J* 2011;18:33–82.
12 Cavagna L, Monti S, Grosso V, et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. *Biomed Res Int* 2013;2013:759760.
13 Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. *Eur Respir Rev* 2021;30:210011.
14 Norton S, Koduri G, Nikiphoro E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. *Rheumatology* 2013;52:99–110.
15 Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. *Respir Med* 2012;106:1164–9.
16 EJ M, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J* 2010;35:1322–8.
17 Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med* 2018;198:e44–88.
18 La Cherasi G, Zamboni M, et al. Hypomethylation of perforin regulatory elements in CD4+ T cells from rat spleens contributes to the development of autoimmune encephalitis. *Respirology* 2014;19:376–81.
19 Yang D-H, Tu C-C, Wang S-G, et al. Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease. *Rheumatol Int* 2014;34:971–7.
21 Hyldgaard C, Bendstrup E, Pedersen AB, et al. Increased mortality among patients with rheumatoid arthritis and COPD: a population-based study. *Respir Med* 2018;140:101–7.

22 Jacob J, Song JW, Yoon H-Y, et al. Prevalence and effects of emphysema in never-smokers with rheumatoid arthritis interstitial lung disease. *EBioMedicine* 2018;28:303–10.

23 Kim HC, Lee JS, Lee EY, et al. Risk prediction model in rheumatoid arthritis-associated interstitial lung disease. *Respirology* 2020;25:1257–64.

24 Nicolau J, Lequerré T, Bacquet H, et al. Rheumatoid arthritis, insulin resistance, and diabetes. *Joint Bone Spine* 2017;84:411–6.

25 Tian Z, Mclaughlin J, Verma A, et al. The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis. *Cardiovasc Endocrinol Metab* 2021;10:125–31.

26 Bai L, Zhang L, Pan T, et al. Idiopathic pulmonary fibrosis and diabetes mellitus: a meta-analysis and systematic review. *Respir Res* 2021;22:175.

27 Rouillé C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. *Semin Arthritis Rheum* 2014;43:613–26.

28 Chen J, Chi S, Li F, et al. Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies. *Expert Opin Biol Ther* 2017;17:265–83.

29 Huang Y, Lin W, Chen Z, et al. Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon? *Drug Des Devel Ther* 2019;13:2111–25.

30 Gao J, Xin L, Guo Q, et al. Twenty-year changes in mortality rates and underlying causes of death in patients with rheumatoid arthritis-associated interstitial lung disease. *Scand J Rheumatol* 2021;50:360–4.